Effect of YM529 on a model of mandibular invasion by oral squamous cell carcinoma in mice

Clinical Cancer Research

Volumn 11, Issue 7, 2005, Pages 2713-2719

  Cui, Nianhui ^a   Nomura, Takeshi ^b   Noma, Hiroyasu ^b   Yokoo, Keiko ^b   Takagi, Ryo ^b   Hashimoto, Sadamitsu ^b   Okamoto, Masato ^c   Sato, Mitsunobu ^c   Yu, Guangyan ^a   Guo, Chuanbin ^a   Shibahala, Takahiko ^b  

^a PEKING UNIVERSITY   (China)

^b TOKYO DENTAL COLLEGE   (Japan)

^c UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 6; MINODRONIC ACID; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE RELATED PROTEIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE METASTASIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE EXPRESSION; MALE; MANDIBLE; MASSETER MUSCLE; MOUSE; MOUTH CARCINOMA; NONHUMAN; ORAL SQUAMOUS CELL CARCINOMA; OSTEOCLAST; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA;

ANIMALS; BODY WEIGHT; BONE RESORPTION; CARCINOMA, SQUAMOUS CELL; CARRIER PROTEINS; CELL LINE, TUMOR; DIPHOSPHONATES; DISEASE MODELS, ANIMAL; GENE EXPRESSION; GLYCOPROTEINS; IMAGING, THREE-DIMENSIONAL; IMIDAZOLES; INTERLEUKIN-6; MALE; MANDIBLE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C3H; MOUTH NEOPLASMS; NEOPLASM INVASIVENESS; OSTEOCLASTS; OSTEOPROTEGERIN; PARATHYROID HORMONE-RELATED PROTEIN; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TOMOGRAPHY, X-RAY COMPUTED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 20244367149     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-1767     Document Type: Article

References (31)

1. Semba I, Matsuuchi H, Miura Y. Histomorphometric analysis of osteoclastic resorption in bone directly invaded by gingival squamous cell carcinoma. J Oral Pathol Med 1996;25:429-35.
2. Okamoto M, Hiura K, Ohe G. et al. Mechanism for bone invasion of oral cancer cells mediated by interleukin-6 in vitro and in vivo. Cancer 2000;89: 1966-75.
3. Shibahara T, Noma H, Nomura T, et al. Bone invasion by gingival squamous cell carcinoma - focus on role of osteoclast-activated cytokines. Jpn J Oral Maxillofac Surg 2003;49:171-8.
4. Tachikawa N. Bone resorbing factors produced by oral squamous cell carcinoma. Jpn J Oral Maxillofac Surg 1990;36:964-78.
5. Horowitz MC, Xi Y, Wilson K, Kacema MA. Control of xosteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands. Cytokine Growth Factor Rev 2001;12:9-18.
6. Suda T, Kobayashi K, Jimi E, Udagawa N, Takahashi N. The molecular basis of osteoclast differentiation and activation. Novartis Found Symp 2001;232:235-50.
7. Palmqvist P, Persson E, Conaway HH, Lerner UH. IL-6, leukemia inhibitory factor, and oncostain M stimulate bone resorption and regulate the expression of receptor activator of NF-κB ligand, osteoprotegerin, and receptor activator of NF-κB in mouse calvariae. J Immunol 2002;169:3353-62.
8. Roux S, Orcel P. Bone loss: Factors that regulate osteoclast differentiation - an update. Arthritis Res 2000;2:451-6.
9. Fleisch H. Bisphophonates: a new class of drugs in diseases of bone and calcium metabolism, recent results. Cancer Res 1989;116:1-28.
10. Sasaki A, Nishiyama A, Alcalde K, et al. Effect of bisphosphonate experimental jaw metastasis model in nude mice. Oral Oncol 1999;35:523-9.
11. Sasaki A, Yoneda T, Terakado N, Alcalde RE, Suzuki A, Matsumura T. Experimental bone metastasis model of the oral and maxillofacial region. Anticancer Res 1998;18:1579-84.
12. Zhang H, Yano S, Miki T, et al. A novel bisphosphonate minodronate (YM529) specifically inhibits osteolytic bone metastasis produced by human small-cell lung cancer cells in NK-cell depleted SCID mice. Clin Exp Metastasis 2003;20:153-9.
13. Yano S, Zhang H, Hanibuchi M, et al. Combined therapy with a new bisphosphonate, minodronate (YM529), and chemotherapy for multiple organ metastasis of small cell lung cancer cells in severe combined immunodeficient mice. Clin Cancer Res 2003;9: 5380-5.
14. Takahashi H, Inokuchi T, Ikeda H, Sekine J, Irie A. Experimental transplantation of carcinoma to tooth extraction sockets: a bone invasion model. Oral Med Pathol 2003;8:61-3.
15. O'Malley BW, Cope KA, Johnson CS, Schwartz MR. A new immunocompetent murine model for oral cancer. Arch Otolaryngol Head Neck Surg 1997;123: 20-4.
16. Krosl G, Korbelik M, Dougherty GJ. Induction of immune cell infiltration into murine SCCVII tumor by photofrin-based photodynamic therapy. Br J Cancer 1995;71:549-55.
17. Fleisch H. Development of bisphosphonates. Breast Cancer Res 2002;4:30-4.
18. Murakami H, Takahashi N, Sasaki T, et al. A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders. Bone 1995;17: 137-44.
19. Clezardin P, Gligorov J, Delmas P. Mechanisms of action of bisphosphonates on tumor cells and prospects for use in the treatment of malignant osteolysis. Joint Bone Spine 2000;67:22-9.
20. Minkin C. Bone acid phosphatase: tartrate-resistant acid phosphatase as a marker of osteoclast function. Calcif Tissue Int 1982;34:285-90.
21. Bonucci E, Nanci A. Alkaline phosphatase and tartrate-resistant acid phosphatase in osteoblasts of normal and pathologic bone. Ital J Anat Embryol 2001; 106:129-33.
22. van de Wijingaert FP, Burger EH. Demonstration of tartrate-resistant acid phosphatase in un-decalcified, glycolmethacrylate-embedded mouse bone: a possible marker for (pre) osteoclast identification. J Histochem Cytochem 1986;34:1317-23.
23. Chappard D, Azema J, Alexandre C, Becker JM. Cytomorphometry of osteoclasts. Med Lab Sci 1989;46:363-6.
24. Kelly JD, McNulty JA, Schneider GB. Quantification of tartrate resistant acid phosphatase activity using a computerized image analysis system. Biotech Histochem 1991;66:228-35.
25. Green JR. Anti-tumor potential of bisphosphonates. Med Klin 2000;95 Suppl:23-8.
26. Fromigue O, Lagneaux L, Body JJ. Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res 2000;15:2211-21.
27. Hiraga T, Williams PJ, Mundy GR, Yoneda T. The bisphosphonate Ibandtonate promotes apoptosis in MDA-MB-213 human breast cancer cells in bone metastases. Cancer Res 2001;61:4418-24.
28. Nishida S, Kikuichi S, Haga H, et al. Apoptosis-inducing effect of a new bisphosphonate, YM529, on various hematopoietic tumor cell lines. Biol Pharm Bull 2003;26:96-100.
29. Rani CSS, MacDougall M. Dental cells express factors that regulate bone resorption. Mol Cell Biol Res Commun 2000;3:145-52.
30. Morony S, Capparelli C, Sarosi I, Lacey DL, Dunstan CR, Kostenuik PJ. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res 2001;61:4432-6.
31. Rodan GA. Bisphosphonates and primary hyperparathyroidism. J Bone Miner Res 2002;17:150-3.